Events occurring after the end of the year

In January 2008, Novozymes announced the closure of the streptococcal-based production of hyaluronic acid (sHA) in China. The decision is of no financial importance for Novozymes and will have no influence on the outlook. The production was acquired in 2006, and significant changes in market conditions lead to the closure. Commercial risks are necessary for Novozymes in order to expand its business and ensure long-term growth. At times, such risks can lead to decisions of this kind.

In the beginning of 2008, uncertainty prevailed on the financial markets, which lead to a general fall in share prices – including the Novozymes share.